ArticleBMC oral health2026
Generalizability of YOLOv11 models for mesiodens detection in pediatric panoramic radiographs.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesiodens is a type of supernumerary tooth in the anterior maxilla with various prevalences. To prevent complications in the future, accurate and precise detection is needed.
objectiveThis study aimed to evaluate and compare YOLOv11-based convolutional neural network (CNN) models for mesiodens detection in pediatric panoramic radiographs using two cloud-based platforms, Roboflow and Ultralytics.
designThis study involved 480 pediatric panoramic radiographs, consisting of 240 mesiodens and 240 no mesiodens images, annotated using Roboflow, with a region of interest (ROI) focused on the anterior maxillary area. The dataset was divided into training (70%), validation (20%), and testing (10%) subsets. Model performance was evaluated using mean average precision (mAP), precision, recall, and F1-score.
resultsThe YOLOv11 Accurate model trained on the Roboflow platform achieved the highest validation mAP50 at 99.2% and recall at 100%. However, its performance declined on inference data, where the F1-score was 84.30%. In contrast, the YOLOv11l model trained on the Ultralytics platform showed more stable performance: its validation mAP was 99.3%, precision was 99.11%, and recall was 94.57%, while the inference F1-score was 96.78%, showing robust generalizability and supporting its suitability for clinical practice.
conclusionYOLOv11l demonstrated the most reliable balance between validation and inference performance, suggesting suitability for clinical application. These results highlight the importance of model generalization rather than peak validation metrics. Future studies should therefore evaluate multicenter datasets and broader clinical settings to confirm robustness and applicability in diverse pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.